A 55-year-old woman was admitted to hospital with pneumonia; she had received a renal transplant for polycystic kidney disease 14 years prior. Her post-transplant history included chronic allograft nephropathy, with a baseline creatinine of 250 (normal 42–102) μmol/L. The patient had no other comorbidities. Her medications included prednisone 5 mg/d, cyclosporine A 50 mg twice daily (average 2-hour postdose cyclosporine level of 500–700 ng/L) and mycophenolate mofetil (MMF) 500 mg twice daily.

Three weeks before her admission, the patient had travelled to a cottage in Prince Edward Island, but reported no contact with farms, animals or bird droppings. The following week, she developed nonbloody diarrhea, and her outpatient transplant team suggested stopping MMF because of its known association with diarrhea. Ten days before admission, the patient developed a mild headache and lethargy, accompanied by dry cough and nausea. The day before admission to hospital, she developed a fever. In the emergency department, the patient was febrile (38.2°C), hypertensive (blood pressure 186/99 mm Hg) and tachycardiac (104 beats/min). The patient’s peripheral oxygen saturation was 97% on room air. Initial bloodwork showed the following: leukocyte count 8.4 (normal 4–11) × 10⁹/L (39% neutrophils, 25% lymphocytes and 34% monocytes) in the CSF. The patient’s opening pressure was 38 (normal < 20) cm H₂O.

An urgent, magnetic resonance imaging (MRI) scan of the brain showed abnormal, bubble-like, T₂-hyperintense signal foci without diffusion restriction involving the bilateral basal ganglia, with mild vasogenic edema (Figure 2). A lumbar puncture showed a protein count of 0.9 (normal 0.15–0.45) g/L, a cerebrospinal fluid (CSF)-to-serum glucose ratio of 48% (normal > 60%), and a leukocyte count of 6 (normal 0–5) × 10⁹/L (39% neutrophils, 25% lymphocytes and 34% monocytes) in the CSF. The patient’s opening pressure was 38 (normal < 20) cm H₂O.

Given the presence of fever, altered level of consciousness, MRI findings of basal ganglia lesions and an elevated opening pressure in this immunocompromised patient, we made a presumptive diagnosis of cryptococcal meningitis. We started empirical treatment with intravenous liposomal amphotericin B at 4 mg/kg/d with oral flucytosine 1500 mg postdialysis. Shortly after we began treatment, the cryptococcal antigen serology came back positive both in the serum and CSF, with a titre of > 1:1024 (Meridian Bioscience Cryptococcal Antigen Latex Agglutination System). On the fourth day after admission, the patient had progressive respiratory decompensation, requiring intubation. On the fifth day, her blood cultures were positive and Cryptococcus neoformans was identified by matrix-assisted laser desorption/ionization. Subsequently, CSF and respiratory cultures also showed heavy growth of C. neoformans. Cerebrospinal fluid bacterial cultures, an acid-fast bacilli smear, viral polymerase chain reaction for herpes viruses and West Nile virus and testing for syphilis were negative. Quantitative blood cytomegalovirus (CMV) polymerase chain reaction was positive at 3.6 × 10⁶ copies/mL and her HIV test was negative.

Disseminated cryptococcal infection in a patient with a remote renal transplant

Kelli Li MD, Abid Khan MD, Sharmistha Mishra MD PhD MSc, Alice Zhabokritsky MD MSc

© 2021 Joule Inc. or its licensors
Our patient had persistently elevated opening pressures requiring daily therapeutic lumbar punctures, targeting a >50% reduction to an opening pressure of <15 cm H₂O. A lumbar drain was placed on day 6, and the following day, prednisone was replaced with a dexamethasone taper to treat the patient’s vasogenic edema. Her CSF culture remained positive until day 9 postadmission, and on day 13, the lumbar drain was removed because the opening pressures had normalized. By week 9, the patient transitioned to consolidation therapy with oral fluconazole 800 mg postdialysis, but there was minimal neurologic recovery. She remained dependent on dialysis throughout her hospital stay. After she experienced recurrent episodes of line-associated and nosocomial sepsis, the patient was transitioned to comfort-focused care after nearly 6 months of being in hospital.

**Discussion**

Cryptococcal infections are the third most common invasive fungal infections in the post-transplant period, after candidiasis and aspergillosis, accounting for 8% of all fungal infections in this population. The incidence of disseminated cryptococcosis in the post-transplant population has been reported to be between
0.3% and 5.3%, according to a review of published reports between 1998 and 2001.\(^2\) Compared with other invasive fungal infections, cryptococcosis has a longer median time to onset from the date of transplant (575 d for cryptococcosis, 103 d for invasive candidiasis and 184 d for aspergillosis).\(^3\)

The epidemiology of invasive cryptococcosis appears to be changing. In Canada, the estimated incidence of invasive cryptococcal infection is 63 per 100,000.\(^4\) Before 2010, cryptococcosis occurred primarily among patients with HIV, and now more than 90% of infections occur in people negative for HIV.\(^5\) This is partially explained by earlier initiation of effective antiretroviral therapy among people with HIV, coupled with an increase in the number of individuals undergoing transplantation and using immunosuppressive medications.

Cryptococcus neoformans and Cryptococcus gattii are the 2 cryptococcal species most commonly associated with infection in humans. C. neoformans has a ubiquitous environmental distribution and can be found in soil, decaying wood and bird droppings.\(^6\) The most common mode of transmission is through inhalation of fungal spores in the environment, which we suspect was the case for our patient. C. neoformans infection is most often reported in immunocompromised patients and is the most common cause of meningitis among patients in the advanced stages of HIV infection.\(^1\) In contrast, C. gattii usually affects immunocompetent hosts,\(^7\) and is typically found in tropical and subtropical regions, although outbreaks have been reported in British Columbia.\(^1,4\)

Cryptococcal meningoencephalitis should be considered in immunocompromised patients with nonspecific neurologic symptoms and fever, as was the case in our patient. More than 75% of patients report an insidious headache, whereas signs of meningismus occur in fewer than 25% of patients.\(^8\) Other common symptoms include altered level of consciousness (about 50%), visual disturbances (about 20%) and seizures or neurologic deficits (< 10%), which may signify a space-occupying lesion such as a cryptococcoma.\(^9\) Radiographic manifestations include meningoencephalitis, granulomas (cryptococcomas) and gelatinous pseudocysts, typically seen in the basal ganglia.\(^7\) Differential diagnosis for basal ganglia lesions in immunocompromised patients includes cryptococcosis, as well as cerebral toxoplasmosis, viral encephalitis and malignant disease.\(^7\)

Immunosuppressive therapy, particularly therapy that affects cell-mediated immunity, influences the risks and outcomes of systemic cryptococcal infections. In general, T-cell–depleting antibodies are associated with the greatest increased risk of cryptococcosis in the post-transplant period.\(^6\) Calcineurin inhibitors, such as cyclosporine A and tacrolimus, are associated with lower 90-day mortality rates and increased long-term survival compared with azathioprine or MMF.\(^7\) Calcineurin inhibitor–based immunosuppressive regimens are also associated with fewer central nervous infections than azathioprine or MMF-based regimens.\(^9\) An increased risk of C. neoformans infection has been reported among patients receiving long-term steroids for autoimmune conditions; however, there is limited evidence linking the dose and duration of steroids and risk of cryptococcal infection among transplant recipients.\(^10\)

Our patient presented with severe disseminated C. neoformans infection 14 years after her renal transplant. We identified another case report describing a patient who presented 13 years after renal transplantation with recurrent urinary tract infections that were eventually linked to a cryptococcoma in the transplanted kidney.\(^11\) The patient in this report had received pulse steroids and changes in her immunosuppressive regimen 3 years before presentation because of rapidly declining renal function. In contrast, our patient was clinically stable on an immunosuppressive regimen of prednisone 5 mg/d for more than 10 years, in combination with cyclosporine A and MMF. In the immediate post-transplant period, her transplant was complicated by acute rejection that was treated with antithymocyte globulin, with no subsequent complications requiring T-cell depletion therapy or pulse steroids.

Our patient had several risk factors for a poor outcome, including a high CSF cryptococcal antigen titre, a decreased CSF-to-serum glucose ratio, an elevated intracranial pressure and an altered level of consciousness.\(^5\) Furthermore, she had concurrent CMV viremia, which has been associated with increased death among patients with AIDS.\(^12\) The impact on morbidity and death from concurrent CMV and opportunistic fungal infections is not well understood in the post-transplant setting. Recent ex vivo data from transplant recipients showed that CMV infection results in blunted cytokine responses to comorbid infections, potentially explaining the immunomodulatory effects of CMV in this population.\(^13\)

**Conclusion**

We report a case of disseminated cryptococcosis with meningoencephalitis, pneumonia and concurrent CMV viremia in a patient who had undergone renal transplantation many years prior and who was on stable immunosuppressive therapy, including low-dose daily prednisone. Invasive fungal infections, such as cryptococcosis, should be considered in patients who present with fever and nonspecific neurologic symptoms, to support early recognition and management.

**References**

1. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network (TRANSNET). *Clin Infect Dis* 2010;50:1101-11.
2. Husain S, Wagener MM, Singh N. *Cryptococcus neoformans* infection in organ transplant recipients: variables influencing clinical characteristics and outcome. *Emerg Infect Dis* 2001;7:379-81.
3. Maziarz EK, Perfect JR. Cryptococcosis. *Infect Dis Clin North Am* 2016;30:179-206.
4. Dufresne SF, Cole DC, Denning DW, et al. Serious fungal infections in Canada. *Eur J Clin Microbiol Infect Dis* 2017;36:397-92.
5. Patel V, Desjardins M, Cowan J. Shift in epidemiology of cryptococcal infections in Ottawa with high mortality in non-HIV immunocompromised patients. *J Fungi (Basel)* 2019;5:104.
6. Zunt JR, Baldwin KJ. Chronic and subacute meningitis. *Continuum (Minneap Minn)* 2012;18:1290-318.
7. Van Cauter S, Severino M, Ammendola R, et al. Bilateral lesions of the basal ganglia and thalami (central grey matter): pictorial review. *Neuroradiology* 2020;62:1565-605.
8. Silveira FP, Husain S, Kwak EJ, et al. Cryptococcosis in liver and kidney transplant recipients receiving anti-thymocyte globulin or alemtuzumab. *Transpl Infect Dis* 2007;9:22-7.

9. Singh N, Alexander BD, Lortholary O, et al. Cryptococcal Collaborative Transplant Study Group. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. *J Infect Dis* 2007;195:756-64.

10. Kerr C, Stack WA, Sadlier C, et al. Disseminated cryptococcal infection initially presenting as cryptococcal cellulitis in an HIV-negative patient on long-term steroids. *BMJ Case Rep* 2018;11:e227249.

11. Muranda AZ, Greeff L, Sathekge MM, et al. Cryptococcoma of a transplanted kidney in a patient presenting with recurrent urinary tract infection: a case report. *BMC Nephrol* 2018;19:52.

12. Skipper C, Schleiss MR, Bangdiwala AS, et al. Cytomegalovirus viremia associated with increased mortality in cryptococcal meningitis in Sub-Saharan Africa. *Clin Infect Dis* 2020;71:525-31.

13. L’Huillier AG, Ferreira VH, Ku T, et al. Improving our mechanistic understanding of the indirect effects of CMV infection in transplant recipients. *Am J Transplant* 2019;19:2495-504.

**Competing interests:** None declared.

This article has been peer reviewed.

The authors have obtained patient consent.

**Affiliations:** Divisions of General Internal Medicine (Li), Nephrology (Khan) and Infectious Diseases (Mishra, Zhabokritsky), Department of Medicine, Faculty of Medicine, University of Toronto; Division of Infectious Diseases (Mishra), Department of Medicine, St. Michael’s Hospital, Unity Health Toronto, Toronto, Ont.

**Contributors:** Kelli Li conceived the work and drafted the manuscript. All authors critically revised the manuscript for important intellectual content, gave final approval of the version to be published and agreed to be accountable for all aspects of the work.

**Content licence:** This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

**Funding:** This work was supported by the Canadian Institutes of Health Research Foundation Grant (FN 13455) for open-access publication fees only.

**Acknowledgement:** The authors thank Dr. Raphael Schneider (Department of Neurology, St. Michael’s Hospital, Toronto, Ont.) for providing a valuable neurology perspective on this case report.

**Correspondence to:** Alice Zhabokritsky, Alice.Zhabokritsky@one-mail.on.ca